Live in harmony with ENTEROLACTIS®: online the new website
Visit the new website dedicated to the complete range of ENTEROLACTIS® products
Visit the new website dedicated to the complete range of ENTEROLACTIS® products
PROTEGGI C, a new Vitamin C based food supplement conveniently packaged with 120 tablets of 1000 mg of Vitamin C
We are proud to announce that our new and futuristic Laboratory, which is also a Center for Research and Development in the field of Microbiota and Probiotics, is now operational!
Innovia KIDS Delivers Safe and Effective Probiotics plus Vitamins Specifically Formulated for Children.
In the sporting year 2019/2020, SOFAR is once again committed to Sport Senza Fron-tiere Onlus – supporting the “Sporty & Healthy” project that helps impoverished children grow healthy, strong and socially fit.
The Romanian market continues to embrace SOFAR’s “Made in Italy” healthcare products; for example, Enterolactis, available in various forms; and Cistiflux, the dietary supplement that promotes urinary tract health.
In the nutraceutical market, SOFAR has once again won top positions in the ranking of healthcare companies.
From January 27th to 30th, SOFAR will participate in this critically important exhibition which is attended by more than 106,500 healthcare professionals who visit over 4,250 exhibitors.
In the sporting year 2019/2020, SOFAR is once again committed to Sport Senza Fron-tiere Onlus – supporting the “Sporty & Healthy” project that helps impoverished children grow healthy, strong and socially fit.
SOFAR participates at CPhI worldwide 2019, the world’s largest pharma event that will host global pharmaceutical experts and entrepreneurs from 5 to 7 November in Frankfurt.
From 7 to 10 November SOFAR will participate in the 104th National Congress of the Italian Society of Orthopedics and Traumatology (SIOT) in Rome.
From 27 to 30 October SOFAR will be at the 94th National Congress of the Italian Gynecology and Obstetrics Society (SIGO) in Naples. The theme of this year’s SIGO Congress is “Gynecology and women. A lifelong journey”.
To introduce Russian consumers to SOFAR’s product and health missions, and engage them in learning more about how our products can benefit them, we have launched social media channels dedicated to the products.
SOFAR will be present at the UEG Week, being held in the prestigious Fira Congress Center in Barcelona from 19 to 23 October 2019.
From October 12 to 15, 2019 SOFAR will be attending the 92nd Annual Congress of the Italian Society of Urology (SIU), which will be held in the Palazzo del Casinò, Venice.
The “Representative office of SOFAR” Moscow has been established with the objective to help improve the quality of life of the millions of Russian patients and consumers.
In October, newly released data from New Line Market Research ranked SOFAR second in the “Best Performer in Pharmacies” in Italy.
From May 23 to 25 SOFAR will be at the Nicolaus Hotel in Bari for the 43rd National Congress of SIA , the Italian Andrology Society.
From the 18th to 21st May, SOFAR will be in the United States for an important convention, the Digestive Disease Week®
Celebrating its 25th anniversary, the annual National Congress of Digestive Diseases, an event hosted by the Italian Federation of Digestive Diseases Society (Fismad), will be held from March 27 to 30, 2019 at the Ergife Hotel in Rome.
SOFAR Americas will participate again in 2019 in the Natural Products Expo West®.
SOFAR is proud to announce that we are continuing our close collaboration with Sport Senza Frontiere ONLUS: a successful initiative that promotes both social inclusion and psychological well-being in children through participation in sports.
From January 28 to 31, 2019 we will be exhibiting at the Arab Health – Dubai in UAE. This event is an important international exhibition that attracts producers and distributors in the healthcare industry.
We are proud to introduce our LP-DG™ probiotic strain (Lactobacillus paracasei DG) into the Australian market where consumers can enjoy its benefit as Biotik™.
In October, newly released data from New Line Market Research ranked SOFAR second in the “Best Performer in Pharmacies” in Italy.
Andrea Biffi, SOFAR’s CEO, summarizes our company’s recent growth in an extensive interview with Fortune Italia.
Following its outstanding success in the US market, our Innovia™ Nectar Digestion has launched throughout Italy.
Dietary supplements as the best performers in August 2018 with a significant increase in turnover (+4.3%)
The time for UEG Week is here again, taking place October 20-24.
SOFAR will be showcasing our innovations at CPhI Worldwide, the premier trade fair for the global pharmaceutical industry, to be held at IFEMA in Madrid, October 9-11.
SOFAR has placed number 3 in the top 10 companies in the dietary supplements category of the non-pharmaceuticals sector in Italy, with a market share of 2.7%, according to New Line Market Research.
In collaboration with the non-profit organization Sport Senza Frontiere, we supported Sporty & Healthy.
SOFAR Announces its Collaboration with Plasma Surgical at the XIII National SEGi Congress
With our Jordanian partner, SOFAR participated in the 14th International Congress of the Jordanian Society of Obstetricians and Gynecologists, which took place in Amman May 2-4, 2018.
Our American subsidiary, SOFAR Americas, will participate in the natural health industry’s premier tradeshow and conference, Natural Products Expo West® (NPEW), from March 9 to 11.
From January 29 to February 1 2018, SOFAR will participate in Arab Health 2018 in Dubai, one of the largest gatherings of healthcare professionals and related commercial entities in the Middle East and North Africa (MENA).
In 1968 SOFAR was founded as an Italian distributor of drugs for third parties. Our company has come a long way since then!
SOFAR’s Enterolactis® holds first place of the top 15 brands in the dietary supplements sector in Italy.
Innovation, research and “Made in Italy” quality have landed in the USA with SOFAR’s distinctive probiotic Innovia Nectar, launched exclusively through our American subsidiary, SOFAR Americas.
Notice is hereby given that, as a result of a partial demerger, effective February 1, 2023, the business unit of Sofar S.p.A. was transferred to Alfasigma S.p.A., which, as of that date, took over for all legal purposes and without interruption all the relationships previously belonging to Sofar S.p.A., including the ownership of the relevant websites and domain names.
In accordance with applicable data protection laws, and in particular in compliance with the Garante per la Protezione dei Dati Personali’s order of April 8, 2009 “Prescrizioni in materia di operazioni di fusione e scissione fra società” (published in the Official Gazette No. 106 of May 9, 2009), Alfasigma S.p.A. will take over as controller of the personal data related to the above-mentioned data already processed by Sofar S.p.A.
Con l’accesso al sito www.sofarfarm.it, dichiarate di aver compreso e accettato le condizioni di utilizzo e le informazioni di carattere legale. Qualora non accettaste tali condizioni, vi preghiamo di non accedere al sito internet di SOFAR S.p.A.